BEAM•benzinga•
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Summary
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 5, 2024 by benzinga